Pernicious Anemia

Parietal cells and intrinsic factor are central to the absorption pathway that delivers vitamin B12 to the terminal ileum. Autoimmune destruction of parietal cells can impair this process, while antibodies directed against intrinsic factor can prevent B12 from being absorbed effectively. The resulting deficiency reflects a failure of uptake rather than simply insufficient dietary intake.

Vitamin B12 deficiency disrupts DNA synthesis during red blood cell development. Cell maturation becomes abnormal, producing enlarged red blood cells with impaired function, a pattern described as macrocytosis and megaloblastic change. These findings provide an important laboratory clue, but they do not by themselves establish pernicious anemia because other causes of B12 deficiency or macrocytosis may produce similar results.

Distinguishing the cause requires combining blood-count findings with vitamin B12 testing and evidence about absorption. Tests for intrinsic-factor antibodies or parietal-cell antibodies can support an autoimmune explanation, while the clinical assessment must also consider other sources of B12 deficiency. This distinction matters because pernicious anemia reflects impaired absorption and requires ongoing clinical attention.

Evaluation commonly begins with a blood count to identify macrocytosis and related abnormalities, followed by vitamin B12 testing to assess deficiency. Clinicians may then assess intrinsic-factor or parietal-cell antibodies when an autoimmune cause is suspected. Interpreting these results together helps separate pernicious anemia from other conditions that can produce B12 deficiency or enlarged red blood cells.

Prompt diagnosis allows clinicians to begin vitamin B12 replacement therapy before deficiency-related problems progress. Treatment can correct the anemia and may limit progressive neurological injury associated with prolonged deficiency. Early identification also establishes the need for long-term clinical monitoring, particularly because the underlying absorption problem is not explained by inadequate dietary intake alone.

Long-term monitoring helps clinicians follow correction of the anemia and assess the continuing clinical consequences of impaired vitamin B12 absorption. It also supports attention to neurological status, because progressive neurological injury is an important concern when deficiency persists. Monitoring therefore extends beyond the initial blood count and helps evaluate the outcome of replacement therapy over time.